{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:31:33Z","timestamp":1791153093006,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2233,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1093\/annonc\/mdt216","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T01:04:24Z","timestamp":1371776664000},"page":"2543-2548","source":"Crossref","is-referenced-by-count":49,"title":["Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"W.","family":"Jonat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ruhstaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.R.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt216_bb0010","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2741\/3723","article-title":"Acquired endocrine resistance in breast cancer: implications for tumour metastasis","volume":"16","author":"Hayes","year":"2011","journal-title":"Front Biosci"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdt216_bb0015","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.3816\/CBC.2009.s.001","article-title":"A 2009 update on the treatment of patients with hormone receptor-positive breast cancer","volume":"9","author":"Cleator","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdt216_bb0020","first-page":"2851","article-title":"Antiprogestins, a new form of endocrine therapy for human breast cancer","volume":"49","author":"Klijn","year":"1989","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdt216_bb0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0959-8049(98)00388-8","article-title":"Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer","volume":"35","author":"Robertson","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt216_bb0030","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.1996.14.10.2709","article-title":"Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study","volume":"14","author":"Perrault","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt216_bb0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0039-128X(00)00195-1","article-title":"Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer","volume":"65","author":"Klijn","year":"2000","journal-title":"Steroids"},{"key":"10.1093\/annonc\/mdt216_bb0040","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1021\/jm001000c","article-title":"Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist","volume":"43","author":"Fuhrmann","year":"2000","journal-title":"J Med Chem"},{"key":"10.1093\/annonc\/mdt216_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mce.2010.11.034","article-title":"The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression","volume":"333","author":"Busia","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1093\/annonc\/mdt216_bb0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsbmb.2009.12.011","article-title":"In vitro characterization of ZK 230211\u2014a type III progesterone receptor antagonist with enhanced antiproliferative properties","volume":"119","author":"Afhuppe","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdt216_bb0055","article-title":"First human data for ZK 230211 (ZK-PRA), a new progesterone receptor antagonist: a Phase I clinical analysis of safety and pharmacokinetics in healthy post-menopausal women","volume":"100","author":"Maibauer","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt216_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt216_bb0065","unstructured":"Guidance for industry. Estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms\u2014recommendations for clinical evaluationhttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071643.pdf 28 February 2013, date last accessed"},{"key":"10.1093\/annonc\/mdt216_bb0070","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.1996.14.7.2000","article-title":"Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group","volume":"14","author":"Buzdar","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt216_bb0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","article-title":"A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer","volume":"32A","author":"Jonat","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt216_bb0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0277-5379(89)90259-9","article-title":"Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy","volume":"25","author":"Robertson","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdt216_bb0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/annonc\/mdf640","article-title":"Endocrine therapy of breast cancer","volume":"13","author":"Goldhirsch","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt216_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/BD-2003-18104","article-title":"Cross-talk between growth factor and progesterone receptor signaling pathways: implications for breast cancer cell growth","volume":"18","author":"Pierson-Mullany","year":"2003","journal-title":"Breast Dis"},{"key":"10.1093\/annonc\/mdt216_bb0095","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.7314\/APJCP.2012.13.4.1111","article-title":"The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact","volume":"13","author":"Ng","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1093\/annonc\/mdt216_bb0100","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00432-008-0414-2","article-title":"Breast cancer patients with estrogen receptor-negative\/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment","volume":"134","author":"Yu","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdt216_bb0105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12253-011-9366-y","article-title":"Estrogen receptor negative and progesterone receptor positive breast carcinomas\u2013how frequent are they?","volume":"17","author":"Cserni","year":"2011","journal-title":"Pathol Oncol Res"},{"key":"10.1093\/annonc\/mdt216_bb0110","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/10\/2543\/16700382\/mdt216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:33:15Z","timestamp":1624519995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419370759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0923753419370759"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt216","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}